Cancer-Associated Fibroblasts As Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33806468

Citations 23

Authors

Sofia Koustoulidou

Mark W H Hoorens

Simone U Dalm

Shweta Mahajan

Reno Debets

Yann Seimbille

Marion de Jong

Affiliations

Soon will be listed here.

Abstract

Cancer Associated Fibroblasts (CAFs) form a major component of the tumour microenvironment, they have a complex origin and execute diverse functions in tumour development and progression. As such, CAFs constitute an attractive target for novel therapeutic interventions that will aid both diagnosis and treatment of various cancers. There are, however, a few limitations in reaching successful translation of CAF targeted interventions from bench to bedside. Several approaches targeting CAFs have been investigated so far and a few CAF-targeting tracers have successfully been developed and applied. This includes tracers targeting Fibroblast Activation Protein (FAP) on CAFs. A number of FAP-targeting tracers have shown great promise in the clinic. In this review, we summarize our current knowledge of the functional heterogeneity and biology of CAFs in cancer. Moreover, we highlight the latest developments towards theranostic applications that will help tumour characterization, radioligand therapy and staging in cancers with a distinct CAF population.

Citing Articles

Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures.

Yang J, Kulkarni N, Yamaji M, Shiraishi T, Pham T, Do H PLoS One. 2024; 19(12):e0314227.

PMID: 39700125 PMC: 11658583. DOI: 10.1371/journal.pone.0314227.

Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors.

Meng S, Hara T, Miura Y, Ishii H Cancer Sci. 2024; 115(11):3532-3542.

PMID: 39169645 PMC: 11531970. DOI: 10.1111/cas.16285.

In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.

van der Heide C, Ma H, Hoorens M, Campeiro J, Stuurman D, de Ridder C EJNMMI Radiopharm Chem. 2024; 9(1):55.

PMID: 39073475 PMC: 11286609. DOI: 10.1186/s41181-024-00283-x.

Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the Ga- and Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi).

Lappchen T, Bilinska A, Pilatis E, Menendez E, Imlimthan S, Moon E Molecules. 2024; 29(13).

PMID: 38999044 PMC: 11243320. DOI: 10.3390/molecules29133093.

Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals.

Sun X, Wu Y, Wang X, Gao X, Zhang S, Sun Z Pharmaceutics. 2024; 16(3).

PMID: 38543239 PMC: 10974899. DOI: 10.3390/pharmaceutics16030345.

References

Trabelsi M, Farah F, Zouari B, Jaafoura M, Kharrat M . An Immunoscore System Based On CD3 And CD8 Infiltrating Lymphocytes Densities To Predict The Outcome Of Patients With Colorectal Adenocarcinoma. Onco Targets Ther. 2019; 12:8663-8673. PMC: 6814319. DOI: 10.2147/OTT.S211048. View

Yuan Y, Jiang Y, Sun C, Chen Q . Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep. 2016; 35(5):2499-515. DOI: 10.3892/or.2016.4660. View

Calais J . FAP: The Next Billion Dollar Nuclear Theranostics Target?. J Nucl Med. 2020; 61(2):163-165. DOI: 10.2967/jnumed.119.241232. View

Ryabtsova O, Jansen K, Van Goethem S, Joossens J, Cheng J, Lambeir A . Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorg Med Chem Lett. 2012; 22(10):3412-7. DOI: 10.1016/j.bmcl.2012.03.107. View

Narra K, Mullins S, Lee H, Strzemkowski-Brun B, Magalong K, Christiansen V . Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007; 6(11):1691-9. DOI: 10.4161/cbt.6.11.4874. View

Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I . Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015; 6:10204. PMC: 4682161. DOI: 10.1038/ncomms10204. View

An Y, Liu F, Chen Y, Yang Q . Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J Cell Mol Med. 2019; 24(1):13-24. PMC: 6933413. DOI: 10.1111/jcmm.14745. View

Muchnik Kurash M, Gill R, Khairulin M, Harbosh H, Keidar Z . 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions. Sci Rep. 2020; 10(1):3109. PMC: 7033090. DOI: 10.1038/s41598-020-60099-y. View

Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L . Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene. 2017; 36(31):4457-4468. PMC: 5507301. DOI: 10.1038/onc.2017.65. View

10.

Powell D . Myofibroblasts: paracrine cells important in health and disease. Trans Am Clin Climatol Assoc. 2000; 111:271-92; discussion 292-3. PMC: 2194356. View

11.

Tomiyama K, Murase N, Stolz D, Toyokawa H, ODonnell D, Smith D . Characterization of transplanted green fluorescent protein+ bone marrow cells into adipose tissue. Stem Cells. 2007; 26(2):330-8. PMC: 2268622. DOI: 10.1634/stemcells.2007-0567. View

12.

Liu R, Li H, Liu L, Yu J, Ren X . Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther. 2012; 13(3):123-9. DOI: 10.4161/cbt.13.3.18696. View

13.

Wang X, Yu D, McCaughan G, Gorrell M . Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 2005; 42(4):935-45. DOI: 10.1002/hep.20853. View

14.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J . Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018; 59(9):1415-1422. DOI: 10.2967/jnumed.118.210443. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Avagliano A, Granato G, Ruocco M, Romano V, Belviso I, Carfora A . Metabolic Reprogramming of Cancer Associated Fibroblasts: The Slavery of Stromal Fibroblasts. Biomed Res Int. 2018; 2018:6075403. PMC: 6008683. DOI: 10.1155/2018/6075403. View

17.

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D . A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018; 59(9):1423-1429. PMC: 6126438. DOI: 10.2967/jnumed.118.210435. View

18.

Roberts E, Deonarine A, Jones J, Denton A, Feig C, Lyons S . Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013; 210(6):1137-51. PMC: 3674708. DOI: 10.1084/jem.20122344. View

19.

Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D . Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7. PMC: 3864274. DOI: 10.1073/pnas.1320318110. View

20.

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View